Pill or procedure?Patient preferences on beta-blockers as an alternative to endoscopic variceal screening during the COVID-19 pandemic

作     者：Zheng Che Jeremy Louissaint Ihab Kassab Elliot B.Tapper 

作者机构：Department of Internal MedicineUniversity of MichiganAnn ArborMIUSA Division of Gastroenterology and HepatologyUniversity of MichiganAnn ArborMIUSA Gastroenterology SectionVA Ann Arbor Healthcare SystemAnn ArborMIUSA 

出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)

年 卷 期：2022年第10卷第1期

页      面：632-634页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：E.B.T.is supported by NIDDK K23 DK117055 

主　　题：esophageal hepatic screening 

摘      要：Introduction Certain patients at low risk of clinically significant esophageal varices by Baveno criteria can safely avoid screening esophagogastroduodenoscopy(EGD)[1,2].However,regardless of variceal status,the PREDESCI study suggests that earlier betablocker(BB)use in compensated disease with clinically significant portal hypertension by hepatic venous pressure gradient may result in benefit by delaying the time to decompensated cirrhosis[3,4].This carries significant ramifications for future clinical guidelines and decision-making for whom we decide to initiate BB.